GlassScriptPhysician profile
William Patrick Fusselman
NPI 1659356228
$848.48
in general payments reported to CMS, 2019-2025
24 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2021: $23.79 · 2022: $77.10 · 2023: $133 · 2024: $217 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $365.69 |
| Education | $109.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $121.92 | 2019 | |
| Janssen Biotech, INC. | $109.79 | 2023-2024 | Imbruvica, Tecvayli |
| Pfizer INC. | $98.69 | 2019-2025 | |
| Abbvie INC. | $88.81 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $73.66 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $57.80 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $35.03 | 2019-2024 | |
| Aveo Pharmaceuticals, INC. | $34.32 | 2024 | |
| Daiichi Sankyo INC. | $26.79 | 2025 | Datroway |
| Seagen INC. | $26.22 | 2022 | |
| Genentech USA, INC. | $25.61 | 2025 | Polivy |
| Janssen Scientific Affairs, LLC | $23.79 | 2021 | |
| Celgene Corporation | $21.36 | 2023 | Reblozyl |
| Lilly USA, LLC | $20.31 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.83 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.27 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.03 | 2024 | Ultomiris |
| Amgen INC. | $14.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.24 | 2022 | |
| Exelixis INC. | $11.00 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Fusselman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.